Active substanceRifampicinRifampicin
Similar drugsTo uncover
  • McCox
    capsules inwards 
  • R-zinc
    capsules inwards 
    Lupine Co., Ltd.     India
  • Rimpin
    capsules inwards 
  • Rifampicin
    lyophilizatesolution d / infusion 
  • Rifampicin
    capsules inwards 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Rifampicin
    capsules inwards 
  • Rifampicin
    capsules inwards 
    VALENTA PHARM, PAO     Russia
  • Rifampicin
    capsules inwards 
    NORTH STAR, CJSC     Russia
  • Rifampicin
    lyophilizatesolution d / infusion 
    KRASFARMA, JSC     Russia
  • Rifampicin
    lyophilizatesolution d / infusion 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Rifampicin-Binergic
    lyophilizatesolution d / infusion 
    BINERGIYA, CJSC     Russia
  • Rifampicin-Binergic
    lyophilizatesolution d / infusion 
    BINERGIYA, CJSC     Russia
  • Rifampicin-Ferein®
    capsules inwards 
    BRYNTSALOV-A, CJSC     Russia
  • Rifampicin-Ferein®
    lyophilizatesolution for injections 
    BRYNTSALOV-A, CJSC     Russia
  • Rifampicin-Ferein®
    lyophilizatesolution d / infusion 
    BRYNTSALOV-A, CJSC     Russia
  • Eremfat
    pills inwards 
  • Eremfat
    lyophilizatesolution d / infusion 
  • Dosage form: & nbsplyophilizate for solution for infusion
    Composition:
    Active substance: rifampicin - 600 mg.

    Excipients: ascorbic acid - 56.0 mg, sodium sulfite - 11.2 mg, sodium hydroxide - 4.0 mg.
    Description:Crystalline powder of red-brown color, caking is allowed.
    Pharmacotherapeutic group:Antibiotic-rifamycin.
    ATX: & nbsp

    J.04.A.B   Antibiotics

    J.04.A.B.02   Rifampicin

    Pharmacodynamics:Semisynthetic broad-spectrum antibiotic, antituberculous drug of the 1st series. At low concentrations, it has a bactericidal effect on Mycobacterium tyberculosis, Brucella spp., Chlamydia trachomatis, Legionella pneumophila, Rickettsia typhi, Mycobacterium leprae; in high concentrations - on some gram-negative microorganisms. Characterized by high activity against Staphylococcus spp. (including penicillinase-forming and many strains of methicillin-resistant), Streptococcus spp., Clostridium spp., Bacillus anthracis; Gram-negative cocci: meningococci, gonococci. Gram-positive bacteria acts in high concentrations. Active with respect to the extracellular and extracellularly located microorganisms. Suppresses the DNA-dependent RNA polymerase of microorganisms. When the drug is monotherapy, the selection of rifampicin-resistant bacteria is observed relatively quickly. Cross-resistance with other antibiotics (with the exception of the other rifamycins) does not develop.
    Pharmacokinetics:Absorption - fast, eating reduces the absorption of the drug. With intravenous administration, the therapeutic concentration is maintained for 8-12 hours. The connection with plasma proteins is 84-91%.

    Rapidly distributed to organs and tissues (the highest concentration in the liver and the kidneys), penetrates into the bone tissue, the concentration in the saliva is 20% of the plasma.The apparent volume of distribution is 1.6 l / kg in adults and 1.1 l / kg in children.

    Through the blood-brain barrier penetrates only in case of inflammation of the meninges. Penetrates through the placenta (concentration in fetal plasma - 33% of the concentration in the mother's plasma) and excreted in breast milk (breastfed babies receive no more than 1% of the therapeutic dose of the drug). Metabolized in the liver with the formation of pharmacologically active metabolite-25-O-deacetyltrifampicin. It is an autoinducer - it accelerates its metabolism in the liver, resulting in a systemic clearance of 6 l / h after the first dose, increases to 9 l / h after repeated administration.

    It is excreted mainly with bile, 80% - in the form of a metabolite; kidneys - 20%. After taking 150-900 mg of the drug, the amount of rifampicin excreted by the kidneys in unchanged form depends on the value of the dose taken and is 4-20%.In patients with impaired renal excretory function, the half-life period is prolonged only in cases when its dose exceeds 600 mg. It is excreted in peritoneal dialysis and hemodialysis. In patients with impaired hepatic function, an increase in rifampicin plasma concentration and an elongation of the half-life period are noted.
    Indications:
    Tuberculosis (all forms) - as part of combination therapy.

    Leprosy (in combination with other antimicrobial drugs, active against Mycobacterium leprae).

    Infectious diseases caused by sensitive microorganisms (in cases of resistance to other antibiotics and in combination antimicrobial therapy, after excluding the diagnosis of tuberculosis and leprosy).

    Brucellosis - as part of combination therapy with antibiotics of the tetracycline group (doxycycline).

    Meningococcal meningitis (prophylaxis in persons who are in close contact with meningococcal meningitis, in Neisseria meningitidis bacilli carriers).
    Contraindications:Hypersensitivity to the drug components, jaundice, recently transferred (less than 1 year) infectious hepatitis, lactation period, chronic renal failure, severe pulmonary heart failure, breast age up to 2 months.
    Carefully:Pregnancy (only for "vital" indications).
    Pregnancy and lactation:Use in pregnancy is possible only if the expected benefit for the mother exceeds the potential risk to the fetus. Therapy during pregnancy (especially in the first trimester) is possible only by "vital" indications. In the appointment of the last weeks of pregnancy may experience post-partum haemorrhage in the mother and the newborn bleeding. In this case, prescribe vitamin K.
    The drug is contraindicated during lactation.
    Dosing and Administration:

    Parenterally - intravenously (intravenously), drip. The injection rate is 60-80 cap / min.

    Intravenous administration of the drug is recommended when sharply progressive and common forms destructive pulmonary tuberculosis, severe purulent-septic processes, if necessary to quickly create high concentrations of the drug in the blood and in the source of infection, in cases where the intake of the drug inside is difficult or poorly tolerated by patients. With intravenous administration, the daily dose for adults is 450 mg, in severe, fast-progressive forms - 600 mg, is administered in a single dose.The duration of intravenous administration depends on the tolerability of the drug and is 1 month or more (with a subsequent transition to oral administration). The total duration of admission for tuberculosis is determined by the effectiveness of treatment and can reach 1 year.

    With infections of non-tuberculous etiology, the daily dose of Rifampicin-Ferein® is 600-900 mg (maximum is 1200 mg). The daily dose is divided into 2-3 injections. The duration of treatment is set individually,

    depends on the effectiveness and can be 7-10 days. Intravenous administration should be discontinued as soon as possible for oral administration. Preparation of the solution for intravenous infusion: dissolve the lyophilizate (600 mg of rifampicin) in 10 ml of water, vigorously shake the vial to ensure complete dissolution of the contents of the vial. The resulting solution is mixed with 500 ml of a 5% dextrose solution. If a smaller dose of rifampicin is needed, the required amount of ml from a vial of dissolved preparation (10 ml = 600 mg of rifampicin, 5 ml to 300 mg of rifampicin, etc.) is taken and mixed with a 5% solution of dextrose. For the treatment of tuberculosis, at least one antituberculous agent is combined (isoniazid, pyrazinamide, ethambutol, streptomycin).Adults with a body weight of less than 50 kg - 450 mg / day; 50 kg and more - 600 mg / day. Children older than 2 months - 10-20 mg / kg / day; the maximum daily dose is 600 mg. With tuberculous meningitis, disseminated tuberculosis, spinal cord injury with neurological manifestations, with a combination of tuberculosis with HIV infection overall treatment duration - 9 months, the drug is used on a daily basis: the first 2 months in combination with isoniazid, pyrazinamide and ethambutol (or streptomycin), 7 months - in combination with isoniazid. In the case of pulmonary tuberculosis and detection of mycobacteria in sputum, apply the following scheme 3 (all of 6 months): The first 2 months - as defined above; 4 months - daily, in combination with isoniazid.

    The first 2 months are as above; 4 months - in combination with isoniazid, 2-3 times during each week. Throughout the course - the reception in combination with isoniazid, pyrazinamide and ethambutol (or streptomycin) 3 times during each week. In those cases when antituberculous drugs

    apply 2-3 times a week (as well as in case of exacerbation of the disease or inefficiency of therapy), their reception must be carried out under the supervision of medical personnel.To treat multibacillary types of leprosy (lepromatous, borderline, lepromatous and borderline) adults - 600 mg once a month in combination with other antimicrobial drugs, active in relation to Mycobacterium leprae; children older than 2 months - 10 mg / kg once a month in combination with other antimicrobial drugs active against Mycobacterium leprae. The minimum duration of treatment is 2 years. For the treatment of multibacillary types of leprosy (tuberculoid and border tuberculosis) adults - 600 mg once a month, in combination with other antimicrobials, active against Mycobacterium leprae; children older than 2 months - 10 mg / kg once a month, in combination with other antimicrobials, active against Mycobacterium leprae. Duration of treatment - 6 months.

    For the treatment of infectious diseases caused by Sensitive microorganisms are prescribed in combination with other antimicrobial agents.

    The daily dose for adults is 600-1200 mg; for children older than 2 months - 10-20 mg / kg. Multiplicity of admission - 2 times a day.

    For the treatment of brucellosis - 900 mg / day once in combination with doxycycline; mean the duration of treatment is 45 days.For the prevention of meningococcal meningitis - 2 times a day every 12 hours for 2 days. Single doses for adults - 600 mg; for children older than 2 months - 10 mg / kg.

    Patients with abnormalities excretory function of the kidneys and

    preserved liver function correction dose is required only in the event that,

    when it exceeds 600 mg / day.

    Side effects:

    From the nervous system: headache, decreased visual acuity, ataxia, disorientation.

    From the digestive system: nausea, vomiting, diarrhea, decreased appetite, erosive gastritis, pseudomembranous enterocolitis; increased activity of "hepatic" transaminases in the blood serum, hyperbilirubinemia, hepatitis, acute pancreatitis.

    From the urinary system: nephronecrosis, interstitial nephritis. Allergic reactions: urticaria, eosinophilia, angioedema, bronchospasm, arthralgia, fever.

    Local reactions: phlebitis at the site of administration.

    Other: leukopenia, dysmenorrhea, induction of porphyria, myasthenia gravis, hyperuricemia, exacerbation of gout.

    With an irregular reception or with the resumption of treatment after a break, there may be: an influenza-like syndrome (fever, chills,headache, dizziness, myalgia), skin reactions, hemolytic anemia, thrombocytopenic purpura, acute renal failure.

    Overdose:
    Symptoms: pulmonary edema, lethargy, confusion, convulsions.

    Treatment: symptomatic; gastric lavage, the appointment of activated charcoal; forced diuresis.
    Interaction:Reduces the activity of indirect anticoagulants, oral hypoglycemic drugs, hormonal contraceptives, cardiac glycosides, antiarrhythmic drugs (disopyramide, pirmenol, quinidine, mexiletine, tokainid), glucocorticosteroids, dapsone, phenytoin, hexobarbital, Iortriptyline, benzodiazepines, sex hormones, theophylline, chloramphenicol, ketoconazole, itraconazole, cyclosporine, azathioprine, beta adrenoblockers, slow calcium channel blockers, enalapril, cimetidinerifampicin causes induction of cytochrome P450 isoenzymes, accelerating their metabolism).
    Isoniazid and / or pyrazinamide increase the frequency and severity of liver function disorders to a greater extent than with the appointment of a single rifampicin, in patients with a previous liver disease.
    Special instructions:
    During treatment the skin, mucus, sweat, feces, lacrimal fluid, urine becomes orange-red color. Can persistently stain soft contact lenses.

    In / in infusion is carried out only under the control of arterial pressure, with prolonged administration, the development of phlebitis is possible.

    Women of reproductive age during treatment should use reliable methods of contraception (oral hormonal contraceptives and additional non-hormonal methods of contraception).

    To prevent the development of resistance of microorganisms, it is necessary to use the drug in combination with other antimicrobial drugs. In the case of a flu-like syndrome, not complicated by thrombocytopenia, hemolytic anemia, bronchospasm, dyspnea, shock, and renal failure in patients receiving medication for intermittent scheme, you should consider switching to a daily intake. In these cases, the dose is increased slowly on the first day prescribe 75-150 mg, and the desired therapeutic dose is achieved in 3-4 days. In the event that the above serious complications are noted, rifampicin cancel.It is necessary to monitor kidney function; an additional prescription of glucocorticosteroids is possible.

    In the case of prophylactic use, meningococcal bacilli carriers require strict monitoring of patients in order to timely identify the symptoms of the disease in the event of rifampicin resistance.

    With prolonged use, a systematic control of the peripheral blood picture and liver function is shown. During the treatment period, it is impossible to apply microbiological methods for determining folic acid and vitamin B12 in the blood serum.
    Effect on the ability to drive transp. cf. and fur:The drug can cause headache and reduced visual acuity, caution is required when managing transport and working with mechanisms.
    Form release / dosage:Lyophilizate for solution for infusion, 600 mg.
    Packaging:
    For 600 mg of rifampicin in bottles with a capacity of 20 ml of glass, hermetically sealed with rubber stoppers, crimped with aluminum caps.



    Each label is labeled with paper for highly artistic publications or a self-adhesive label.

    1 bottle with the drug, along with instructions for use, is placed in a pack of cardboard.Five vials of the drug are placed in a contour mesh package made of a polyvinyl chloride film.

    Five vials of the drug are placed in a contour mesh package made of a polyvinylchloride film and a flexible package based on aluminum foil or a packaging material combined on a paper basis. 1 or 2 contoured cell packs with vials together with instructions for use are placed in a pack of cardboard.

    Packing for hospitals

    For 10 contour packs with vials together with an equal number of instructions for use are placed in a box of cardboard.
    Storage conditions:In the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:
    4 years. Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-002308
    Date of registration:25.11.2013
    Date of cancellation:2018-11-25
    The owner of the registration certificate:BRYNTSALOV-A, CJSC BRYNTSALOV-A, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp13.05.2016
    Illustrated instructions
      Instructions
      Up